open access

Vol 11, No 5 (2006)
Published online: 2006-01-01
Submitted:
Get Citation

Expression of selected markers in patients treated for breast cancer – based on our own data

Sylwia Grodecka-Gazdecka, Robert Gryczka, Mikołaj Musiał, Tomasz Graja
DOI: 10.1016/S1507-1367(06)71068-9
·
Rep Pract Oncol Radiother 2006;11(5):229-234.

open access

Vol 11, No 5 (2006)
Published online: 2006-01-01
Submitted:

Abstract

Background

Breast cancer patients’ long-term survival rate depends on many factors, such as the biological features of the tumour, stage of disease and mode of treatment. In most cases, in management of breast cancer combination therapy is used, according to indications. Qualification for adjuvant therapy is based on the assessment of several factors of established prognostic and predictive values. As a standard the patient's age, primary tumour size, axillary lymph node involvement, cancer histological type, its malignancy grade and steroid receptor expression are considered.

Aim

Analysis of status of selected immunohistochemical markers in a set of consecutive patients undergoing surgery for breast cancer.

Materials/Methods

Samples from 623 patients were examined. Colour reaction was used for oestrogen (ER) and progesterone (PgR) receptors, P53 protein, cathepsin D and c-erbB-2. Overexpression of HER-2 protein was examined in 150 patients.

Results

The presence of oestrogen receptors in cell nuclei was detected in 431 (69.2%) patients, of progesterone receptors in 504 (80.2%), and ER+, PgR+ phenotype in 382 (61%) patients. Cathepsin D expression was observed in 438 (70.3%) subjects. In 176 (27.3%) patients P53 protein accumulation was observed. Oncoprotein c-erbB-2 overexpression was observed in 99 (15.9%) and overexpression of HER-2 receptor in 29 (19.8%) patients.

Conclusions

Nowadays oestrogen receptors are detected more frequently than in patients treated in the years 1980–1986. Detection rates of cathepsin D and P53 protein expression remain at comparable levels. The difference observed in detection rate of c-erbB-2 expression requires further analysis. Assessment of the correlation between expression of studied immunohistochemical markers and survival rate is necessary.

Abstract

Background

Breast cancer patients’ long-term survival rate depends on many factors, such as the biological features of the tumour, stage of disease and mode of treatment. In most cases, in management of breast cancer combination therapy is used, according to indications. Qualification for adjuvant therapy is based on the assessment of several factors of established prognostic and predictive values. As a standard the patient's age, primary tumour size, axillary lymph node involvement, cancer histological type, its malignancy grade and steroid receptor expression are considered.

Aim

Analysis of status of selected immunohistochemical markers in a set of consecutive patients undergoing surgery for breast cancer.

Materials/Methods

Samples from 623 patients were examined. Colour reaction was used for oestrogen (ER) and progesterone (PgR) receptors, P53 protein, cathepsin D and c-erbB-2. Overexpression of HER-2 protein was examined in 150 patients.

Results

The presence of oestrogen receptors in cell nuclei was detected in 431 (69.2%) patients, of progesterone receptors in 504 (80.2%), and ER+, PgR+ phenotype in 382 (61%) patients. Cathepsin D expression was observed in 438 (70.3%) subjects. In 176 (27.3%) patients P53 protein accumulation was observed. Oncoprotein c-erbB-2 overexpression was observed in 99 (15.9%) and overexpression of HER-2 receptor in 29 (19.8%) patients.

Conclusions

Nowadays oestrogen receptors are detected more frequently than in patients treated in the years 1980–1986. Detection rates of cathepsin D and P53 protein expression remain at comparable levels. The difference observed in detection rate of c-erbB-2 expression requires further analysis. Assessment of the correlation between expression of studied immunohistochemical markers and survival rate is necessary.

Get Citation

Keywords

Breast cancer; immunohistochemical markers

About this article
Title

Expression of selected markers in patients treated for breast cancer – based on our own data

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 11, No 5 (2006)

Pages

229-234

Published online

2006-01-01

DOI

10.1016/S1507-1367(06)71068-9

Bibliographic record

Rep Pract Oncol Radiother 2006;11(5):229-234.

Keywords

Breast cancer
immunohistochemical markers

Authors

Sylwia Grodecka-Gazdecka
Robert Gryczka
Mikołaj Musiał
Tomasz Graja

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl